FOIU 2018: Cytoreductive Nephrectomy in the Tyrosine Kinase Inhibitors Era: The CARMENA Study
Tel-Aviv, Israel (UroToday.com) Arnaud Mejean, MD presented the CARMENA trial and what led to the creation of this trial. In the past cytoreductive nephrectomy (CN) has been a treatment option for carefully selected patients with metastatic renal cell carcinoma (MRCC). Clinical trials have demonstrated that those patients with an estimated survival of less than 12 months or those with four or more IMDC criteria (anemia thrombocytosis, Neutrophilia, Karnofsky Performance Status (KPS) <80 percent, and less than 1 year from diagnosis to treatment) may not benefit from nephrectomy.1
FOIU 2018: Should the Primary Be Treated in Patients with Metastatic Disease? - Kidney Cancer
Tel-Aviv, Israel (UroToday.com) Gennady Bratslavsky, MD gave a talk discussing the question of whether we should treat the primary tumor in metastatic renal cell carcinoma (MRCC). The outline of his talk included these topics:
- Current guidelines for metastatic RCC.
- Rational behind cytoreductive nephrectomy (CN).
- Historical evidence supporting current guidelines
- Discussion on the CARMENA trial.
FOIU 2018: Current Experience in Immunotherapy for Metastatic Renal Cell Carcinoma
Tel-Aviv, Israel (UroToday.com) Axel Bex, MD gave an overview of immunotherapy in metastatic renal cell carcinoma (MRCC). Immune checkpoint inhibitors (ICI) have changed the RCC treatment landscape. Checkmate 025 trial which compared Nivolumab vs. Everolimus in 2nd line MRCC demonstrated an improved median overall survival (OS) for nivolumab of 25 vs. 19.6 months, p=0.002.